Biopharmaceutical services provider Parexel has entered a multi-year collaboration with healthcare data services firm Datavant to link real-world data across clinical trials.

Parexel will combine Datavant’s connectivity technology with standard data workflow for all of its studies. This will enable sponsors to streamline evidence generation via the connection of real-world data to their trial data.

The data connection can be made in the trial protocol or after the completion of a study.

Parexel CEO Jamie Macdonald said: “Across the industry, real-world evidence is becoming an essential component to evaluating the safety and effectiveness of drug therapies and ultimately to delivering therapeutic advances. However, one of the most significant barriers to generating real-world evidence is overcoming limitations of single data sources.

“Partnering with Datavant has provided Parexel the ability to link disparate data sets to drive the complex analyses necessary for providing innovative scientific and clinical data strategies.”

Datavant’s technology can be used to connect data across the patient journey, including electronic health records, claims, and diagnostics with other emerging sources, such as genomics, socioeconomic and behavioural data.

The connection between real-world data sources and other study data sources is intended to help biopharmaceutical customers generate and submit real-world evidence required for regulatory review.

The partnership will also provide Parexel with opportunities for collaborations with organisations using Datavant software, including academic medical centres, life sciences and medical device companies, insurers, data aggregators, and analytics companies.

Datavant co-founder and CEO Travis May said: “Parexel’s deep clinical expertise positions them well to navigate the planning necessary to include real-world data in the drug development process, and our join solution gives Parexel’s sponsors the flexibility to leverage the real-world data they need, whenever they need it, all while ensuring that patient privacy is protected.”